Cover Image
市場調查報告書

HER2陰性乳癌的全球市場:2015年∼2019年

Global HER2-Negative Breast Cancer Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 341167
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
HER2陰性乳癌的全球市場:2015年∼2019年 Global HER2-Negative Breast Cancer Market 2015-2019
出版日期: 2015年09月30日 內容資訊: 英文 50 Pages
簡介

HER2陰性乳癌的全球市場,預計從2014年到2019年之間,以15.94%的年複合成長率擴大。

本報告提供全球HER2陰性乳癌市場各藥物分子類型、各給藥途徑,與各地區的規模和今後的預測、市場成長要素與課題、主要趨勢、競爭分析等,為您概述為以下內容。

第1章 摘要整理

  • 概況

第2章 本報告的調查範圍

  • 市場概要
  • 主要供應商的產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場概況

第5章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第6章 各藥物分子類型的市場分類

  • 生技藥品
  • 小分子

第7章 各給藥途徑的市場分類

  • 口服
  • 非口服

第8章 地理區分

  • 各地區的市場分類
  • 南北美洲的HER2陰性乳癌市場
  • 歐洲、中東、非洲地區的HER2陰性乳癌市場
  • 亞太地區的HER2陰性乳癌市場

第9章 開發平台、組合

  • 開發平台的最後階段的候補藥的主要資訊

第10章 市場成長因素

第11章 市場成長因素的影響

第12章 市場課題

第13章 成長因素與課題的影響

第14章 市場趨勢

第15章 業者情勢

  • 競爭模式
  • 主要消息
  • M&A
  • 市場佔有率分析
  • Other and future 有力供應商

第16章 主要供應商分析

  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer

第17章 附錄

  • 簡稱清單

第18章 關於ETechnavio

目錄
Product Code: IRTNTR7383

About HER2-negative breast cancer

HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer. HER2-negative breast cancer patients can also be hormone receptor positive (HR+). The HER2 protein is found on the outer surface of the breast cells, and the hormone receptors are found inside breast cells. The cancers that have detectable hormone receptors are known as HR+ breast cancer, and those with HER2-negative have a low level of HER2 gene or the HER2 protein. HER2-negative breast cancer can also be HR+ and then the most preferred therapy is hormone therapy. These patients can be treated with chemotherapy or targeted therapy to improve their condition. It can also be treated with platinum-based drugs, and drugs such as capecitabine, eribulin, gemcitabine, ixabepilone, and vinorelbine. These drugs have several adverse effects on patients as some of them can attack the healthy cells of the body while destroying the malignant cells.

Technavio's analysts forecast the global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer.

Based on type of drug molecule, the market is segmented as follows:

  • Biologics
  • Small molecules

Based on route of administration, the market is segmented as follows:

  • Oral
  • Parenteral

This report includes a discussion of the market in the following three regions:

  • Americas (the US, Canada, Mexico, and Brazil)
  • EMEA (the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE)
  • APAC (Japan, China, Australia, Singapore, South Korea, and India)

Technavio's report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer

Other Prominent Vendors

  • AbbVie
  • AstraZeneca
  • BioMarin
  • Bristol-Myers Squibb
  • Eisai
  • Eli Lilly
  • Galena Biopharma
  • Incyte
  • Merck
  • Merck Serono
  • Merrimack
  • Nektar
  • Tesaro

Key market driver

  • Significant unmet needs
  • For a full, detailed list, view our report

Key market challenge

  • Premium-priced therapies
  • For a full, detailed list, view our report

Key market trend

  • Emerging therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by type of drug molecule

  • Biologics
  • Small molecules

PART 07: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 08: Geographical segmentation

  • Market segmentation by geography 2014-2019
  • HER2-negative breast cancer market in Americas 2014-2019
  • HER2-negative breast cancer market in EMEA 2014-2019
  • HER2-negative breast cancer market in APAC 2014-2019

PART 09: Pipeline portfolio

  • Key information about late-stage pipeline candidates

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Market share analysis
  • Other and future prominent vendors

PART 16: Key vendor analysis

  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer

PART 17: Appendix

  • List of abbreviations

PART 18: EExplore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global HER2-negative breast cancer market 2014-2019 ($ billions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Segmentation of global HER2-negative breast cancer market by geography 2014
  • Exhibit 05: HER2-negative breast cancer market in Americas 2014-2019 ($ millions)
  • Exhibit 06: HER2-negative breast cancer market in EMEA 2014-2019 ($ millions)
  • Exhibit 07: HER2-negative breast cancer market in APAC 2014-2019 ($ millions)
  • Exhibit 08: Region-wise comparison of market size 2014-2019 ($ millions)
  • Exhibit 09: Major pipeline drug candidates in phase III stage of development
  • Exhibit 10: Impact of drivers
  • Exhibit 11: Impact of drivers and challenges
  • Exhibit 12: Vendor ranking 2014
  • Exhibit 13: Key takeaways: F. Hoffmann-La Roche
  • Exhibit 14: Novartis: Sales and YoY growth of Afinitor 2012-2014 ($ millions)
  • Exhibit 15: Key takeaways: Novartis
  • Exhibit 16: Key takeaways: Pfizer
  • Exhibit 17: Business segmentation 2013 and 2014 by revenue ($ billions)
  • Exhibit 18: Geographical segmentation by revenue 2014
Back to Top